Keith Bartolomei, MD
Nephrology · Providence, RINPI 1568667434
Payments from drug & device makers
Across 537 payments — averaging $173.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$36K
- AstraZeneca$34K
- Bayer$11K
- Otsuka America Pharmaceutical, Inc.$6K
- Vifor Pharma, Inc.$830
- Amgen$766
- plus $5K from 24 others
What the payments were for
- Speaking & faculty fees$4,91033%
- Food & beverage$9,40063%
- Education$5904%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 32 | $35,535 |
| AstraZeneca(2 entities) | 87 | $34,194 |
| Bayer | 29 | $11,310 |
| Otsuka America Pharmaceutical, Inc. | 50 | $5,778 |
| Vifor Pharma, Inc. | 56 | $830 |
| Amgen(2 entities) | 29 | $766 |
| OPKO Pharmaceuticals, LLC | 44 | $730 |
| GSK | 30 | $502 |
| Boehringer Ingelheim | 23 | $446 |
| Calliditas Therapeutics US Inc. | 17 | $437 |
| Fresenius USA Marketing, Inc. | 23 | $405 |
| Akebia Therapeutics Inc | 17 | $373 |
| Travere Therapeutics, Inc. | 19 | $352 |
| Arbor Pharmaceuticals, Inc. | 23 | $258 |
| Daiichi Sankyo Inc. | 5 | $211 |
| Novo Nordisk | 7 | $188 |
| Ardelyx, Inc. | 8 | $179 |
| Mallinckrodt Hospital Products Inc. | 7 | $150 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $117 |
| Lexicon Pharmaceuticals, Inc. | 5 | $105 |
| Johnson & Johnson | 6 | $95 |
| Novartis | 3 | $75 |
| Alnylam Pharmaceuticals Inc. | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Strongbridge US Inc. | 3 | $38 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$4,910
- INJECTAFER$142
- KRYSTEXXA$119
- Parsabiv$108
How this compares
$93,253 in reported general payments places this provider in the 80th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 23 | $452,203 |
| VelphoroSucroferric Oxyhydroxide | 48 | $106,435 |
| VeltassaPatiromer Calcium Sorbitex | 96 | $72,921 |
| FarxigaDapagliflozin Propanediol | 89 | $59,496 |
| XphozahTenapanor Hcl | 17 | $54,338 |
| JardianceEmpagliflozin | 34 | $29,444 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $20,990 |
| AuryxiaFerric Citrate | 11 | $15,718 |
| KerendiaFinerenone | 21 | $14,420 |
| RayaldeeCalcifediol | 12 | $13,665 |
| Lanthanum Carbonate | 20 | $6,540 |
| Sevelamer Carbonate | 53 | $6,483 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 11 | $5,233 |
| EdarbiAzilsartan Medoxomil | 16 | $4,912 |
| Chlorthalidone | 113 | $2,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $5,778 | $452,20323 claims |
| Fresenius USA Marketing, Inc.Velphoro | $405 | $106,43548 claims |
| AstraZenecaFarxiga, Lokelma | $34,194 | $80,486126 claims |
| Boehringer IngelheimJardiance | $446 | $29,44434 claims |
| Akebia Therapeutics IncAuryxia | $373 | $15,71811 claims |
| BayerKerendia | $11,310 | $14,42021 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $730 | $13,66512 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $258 | $10,14527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 45 nephrology providers in Rhode Island.
Other nephrology in Providence
- Elkin EstradaProvidence$277K
- Jonah LichtProvidence$207K
- Katherine DavorenProvidence$9K
- Jeffrey ClementProvidence$7K
- Devyani SivakumarProvidence$5K
- Muhammad LiaqatProvidence$4K
- Amol MittalProvidence$3K
- Marc WeinbergProvidence$3K
- Alay NanavatiProvidence$537
- Shijo BenjaminProvidence$491
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.